Current Affairs - Science

AdFalciVax is India’s first indigenous recombinant chimeric malaria vaccine candidate, designed to combat the deadly Plasmodium falciparum parasite. It is a multi-stage vaccine that targets two critical stages of the parasite’s life cycle, enhancing its effectiveness against malaria. Developed through a collaborative effort between the Indian Council of Medical Research (ICMR) and the Department of Biotechnology–National Institute of Immunology (DBT–NII), this innovative vaccine represents a significant milestone in India’s public health and biomedical research initiatives. AdFalciVax reflects the country’s growing capabilities in tackling infectious diseases through indigenous scientific advancements.

Switzerland, through its medical authority Swissmedic, approved the world’s first malaria medicine for infants weighing between 2 and 5 kilograms on July 9, 2025. This groundbreaking approval was for a drug developed by Novartis, a Swiss pharmaceutical company based in Basel. The approval was granted under a fast-track process in partnership with the World Health Organisation to ensure quicker access in developing countries. The new treatment targets vulnerable infants who previously relied on less suitable medications adjusted from those made for older children. This is especially significant for Africa, where infant malaria remains a leading cause of child mortality.

Coartem is the first-ever malaria drug that has been approved for use specifically in newborns and very young children, marking a significant milestone in the fight against malaria. Developed by Novartis, this drug received approval from Swiss authorities and aims to reduce the high mortality rate of malaria among infants, particularly in Africa, where the majority of malaria-related deaths occur. In 2023 alone, malaria caused over half a million deaths worldwide, highlighting the critical need for targeted treatments like Coartem to protect the most vulnerable populations.

Scientists from France’s national blood agency, Établissement Français du Sang (EFS), discovered a completely new blood group system named EMM-negative. This new type has been officially recognized by the International Society of Blood Transfusion (ISBT). The discovery was made after identifying the rare blood type in a woman from Guadeloupe, leading to the colloquial name “Gwada negative.” This marks a significant advancement in haematology and could have important implications for blood transfusions and compatibility testing in the future.

AIIMS Mangalagiri organized an awareness rally on June 19, 2025, in Andhra Pradesh to observe World Sickle Cell Day. The event was held in collaboration with the Departments of Health, Family Welfare, and Tribal Welfare. The initiative aimed to raise awareness about sickle cell disease, particularly in tribal communities where the prevalence is higher. Key officials and community members participated in the event, emphasizing a unified commitment toward eliminating the genetic disorder by 2047 under India’s National Sickle Cell Elimination Mission. AIIMS Mangalagiri’s active engagement demonstrates its pivotal role in public health education and tribal outreach.